- $1.70bn
- $1.38bn
- $62.90m
Annual balance sheet for Nuvation Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 765 | 661 | 611 | 503 | 529 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.04 | 2.48 | 3.7 | 16.3 | 19.4 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 772 | 667 | 616 | 526 | 572 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.66 | 4.68 | 4.32 | 2.99 | 4.48 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 776 | 672 | 621 | 541 | 595 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 16.9 | 13.2 | 14 | 58.2 | 82.2 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 30.2 | 17.1 | 16.4 | 76.8 | 289 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 746 | 655 | 605 | 464 | 306 |
| Total Liabilities & Shareholders' Equity | 776 | 672 | 621 | 541 | 595 |
| Total Common Shares Outstanding |